Development of Novel Therapies for NIDDM

Sponsor

Duke University (Other)

Overall Status

Completed

CT.gov ID

NCT01905722

Collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH), University of Texas Southwestern Medical Center (Other)

Enrollment

Location

Arms

41.2

Actual Duration (Months)

1.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Project 4 of the grant, led by Dr. Craig Malloy at UTSW, will develop and apply new technology in MRI to test core hypotheses about the development of insulin resistance in people. The long-term goal is to develop technology to monitor metabolism in skeletal muscle, brain and the liver using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) in a 3 Tesla and 7 Tesla MRI scanners. These advanced imaging methods allow researchers to take pictures of the inside of the body and to measure metabolism as it occurs in the MRI scanner. Standard clinical MRI for medical diagnosis and treatment is performed in a 1 Tesla or 3 Tesla MRI scanner.

A primary goal of the 7 Tesla research program is to develop a group of protocols for investigating specific metabolic pathways in adipose (fat) tissue, skeletal muscle and the liver. This study is being done to improve methods of imaging and measuring molecules in a 3 Tesla or 7 Tesla scanners.

Condition or Disease	Intervention/Treatment	Phase
Metabolism	Other: 3 Tesla Other: 7 Tesla	N/A

Detailed Description

The overarching goal of this program project grant is the development of technologies that lead to new methods for studying, detecting, and treating type 2 diabetes, and their integration with hypothesis-driven diabetes research projects. The research will be led by an Administrative Core team (Core C) under the direction of Dr. Newgard at the Sarah W. Stedman Nutrition and Metabolism Center at Duke to ensure the integration of all analyses in the Projects and Cores. Research within the PPG will be supported by two established scientific core laboratories including the mass spectrometry (MS)-based metabolic profiling core (Core

of Duke Stedman Center Metabolomics Core Laboratory directed by James Bain, Ph.D. and the Metabolomic flux/Imaging Core (Core A) at the Advanced Imaging Research Center (AIRC) of the University of Texas Southwestern Medical Center under the direction of Dean Sherry, Ph.D.

Projects 1-3 of the current program continue the animal model work of the previous research and Project 4, to be conducted at UTSWMC, adds a human studies component as well as additional animal studies. The goal of Project 1 (led by Dr. Newgard/Duke) is to collaborate with the other projects and cores to fully understand the metabolic and molecular changes that lead to perturbed branched-chain amino acid (BCAA) homeostasis and loss of insulin sensitivity in animal models, thereby leading to better understanding of possible cause/effect relationships between BCAA and metabolic disease. The goal of Project 2 (led by Dr. Muoio/Duke), also working with the other components of the program, is to test the hypothesis that excessive mitochondrial catabolism of lipid and BCAA plays a central role in triggering mitochondrial stress, insulin resistance and eventual metabolic failure in skeletal muscle during the pathological progression of diet-induced obesity. Project 3 (led by Dr. Burgess/UTSWMC) uses the tools in Cores A and B to help define the temporal sequence of changes in mitochondrial metabolism in liver during development of hepatic insulin resistance, and also dissects the contribution of key signaling events (insulin receptor engagement, mTOR activation) and nutrients (BCAA, lipids) in this process. Project 4 (led by Dr. Malloy at UTSWMC) will develop and apply novel high-field 7T NMR spectroscopy/metabolic flux analysis technologies to help test three core hypotheses about the development of insulin resistance emanating from Projects 1-3 (animal studies) in human subjects.

For project 4, the current request is to establish a protocol to vary the site of 13C labeling in several physiological molecules: glucose, lactate, acetate, pyruvate, and octanoate. All of these molecules can undergo oxidation in the citric acid cycle and all can be safely administered to human subjects. The intent is to study a particular 13C labeling pattern and molecule in 70 subjects to determine if downstream products (such as 13C bicarbonate or 13C glutamate) due to oxidation in the mitochondria can be detected in skeletal muscle or in blood by NMR analysis.

Additional work will include using 31P imaging to probe mitochondrial function by measuring phosphorus-containing metabolites, as well as pH and metabolic flux activities non-invasively.

Aim 3 of this project to commence in September of 2014 is a cross-sectional study in overweight humans with measurements of branched-chain amino acids (BCAA) to test mitochondrial function in skeletal muscle using 7T 31P imaging and an insulin clamp (infusion of a glucose tracer). Subjects for the Aim 3 phase of the study will be 25 to 60 years of age.

These new high-field MR technologies will be integrated with those largely in hand for understanding mitochondrial function in liver and skeletal muscle in a project that translates the biological/mechanistic findings of all these grant projects to human studies.

This protocol is primarily for technology development. Most of the subjects will undergo a 7T MR exam as optimal information is expected from the stronger field strength. The 3T MR scanner will be used once a protocol has been established for comparison.

Study Design

Study Type:

Interventional

Actual Enrollment :

64 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Basic Science

Official Title:

Development of Novel Therapies for NIDDM: Technology Development for Mitochondrial Substrate Oxidation at 3 Tesla and 7 Tesla

Actual Study Start Date :

Dec 10, 2013

Actual Primary Completion Date :

May 17, 2017

Actual Study Completion Date :

May 17, 2017

Arms and Interventions

Arm	Intervention/Treatment
Other: 3 Tesla 3 Tesla scanning with intravenous infusion of tracers	Other: 3 Tesla 3 Tesla scanning with intravenous infusion of tracers
Experimental: 7 Tesla 7 Tesla scanning with intravenous infusion of tracers	Other: 7 Tesla 7 Tesla scanning with intravenous infusion of tracers

Arm

Intervention/Treatment

Other: 3 Tesla

3 Tesla scanning with intravenous infusion of tracers

Other: 3 Tesla

3 Tesla scanning with intravenous infusion of tracers

Experimental: 7 Tesla

7 Tesla scanning with intravenous infusion of tracers

Other: 7 Tesla

7 Tesla scanning with intravenous infusion of tracers

Outcome Measures

Primary Outcome Measures

Identification of metabolic tracers for optimal data in future metabolic studies. [90 minutes]
The primary outcome measure will be the identification of metabolic tracers that will yield optimal data to apply to disease processes in future metabolic studies.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 60 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Good general health (normal vital signs; no acute signs or symptoms of illness)
Able to give informed consent
Able to tolerate study procedures including insertion of an intravenous catheter and approximately 90 minutes in the MRI scanner
Aim 3 phase subjects will have BMI of 28 to 35 and a sedentary lifestyle; may be pre-diabetic or have undiagnosed type 2 diabetes

Exclusion Criteria:

Known diagnosed disease, including known heart rhythm disturbance, cancer or risk of seizure disorder or other disorder that could create risk to the subject
Pregnancy
Subjects with implanted metal that would compromise safety in MR use
Subjects not fluent in English will be excluded because the immediate ability to respond to instructions in the scanner is required

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Texas Southwestern Medical Center	Dallas	Texas	United States	75390

Sponsors and Collaborators

Duke University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of Texas Southwestern Medical Center

Investigators

Principal Investigator: Christopher Newgard, PhD, Duke University
Principal Investigator: Craig R. Malloy, MD, University of Texas Southwestern Medical Center